Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 4Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Hormone Treatment-naïve Participants With Prostate Cancer 1Endometriosis 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has results × relugolix × Clear all
NCT02141659 2018-11-19

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Takeda

Phase 1 Completed
43 enrolled 23 charts
Genitourinary

Hormone Treatment-naïve Participants With Prostate Cancer

NCT02093390 2016-06-06

A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
40 enrolled 23 charts
Genitourinary

Endometriosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡